RT Journal Article
SR Electronic
T1 Proteome-wide autoantibody screening and holistic autoantigenomic analysis unveil COVID-19 signature of autoantibody landscape
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.07.24308592
DO 10.1101/2024.06.07.24308592
A1 Matsuda, Kazuki M
A1 Kawase, Yoshiaki
A1 Iwadoh, Kazuhiro
A1 Kurano, Makoto
A1 Yatomi, Yutaka
A1 Okamoto, Koh
A1 Moriya, Kyoji
A1 Kotani, Hirohito
A1 Hisamoto, Teruyoshi
A1 Kuzumi, Ai
A1 Fukasawa, Takemichi
A1 Yoshizaki-Ogawa, Asako
A1 Kono, Masanori
A1 Okamura, Tomohisa
A1 Shoda, Hirofumi
A1 Fujio, Keishi
A1 Yamaguchi, Kei
A1 Okumura, Taishi
A1 Ono, Chihiro
A1 Kobayashi, Yuki
A1 Sato, Ayaka
A1 Miya, Ayako
A1 Goshima, Naoki
A1 Uchino, Rikako
A1 Murakami, Yumi
A1 Matsunaka, Hiroshi
A1 Imai, Hiroshi
A1 Sato, Shinichi
A1 Raymond, Rudy
A1 Yoshizaki, Ayumi
YR 2024
UL http://medrxiv.org/content/early/2024/06/08/2024.06.07.24308592.abstract
AB This study presents “aUToAntiBody Comprehensive Database (UT-ABCD)”, a proteome-wide catalog of autoantibody profiles in 284 human individuals. The subjects included patients diagnosed with Coronavirus disease 2019 (COVID-19), systemic sclerosis (SSc), systemic lupus erythematosus (SLE), anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), atopic dermatitis (AD), as well as healthy controls (HC). Our investigation employed proteome-wide autoantibody screening (PWAS) that utilizes 13,350 autoantigens displayed on wet protein arrays, covering approximately 90% of the human transcriptome. Our findings demonstrated significant elevation of autoantibody levels in COVID-19, SSc, and SLE patients. Unique sets of disease-specific autoantibodies were identified, highlighting the role of autoantibodies against proteins associated with cytokine signaling in immune systems and viral infection pathways. Employing machine learning, we distinguished COVID-19 cases with high accuracy based on autoantibody profiles, notably identifying antibodies against proteins encoded by BCORP1 and KAT2A as highly specific to COVID-19. Longitudinal analysis revealed dynamic changes in autoantibody levels throughout the course of COVID-19, independent of disease severity. Our research highlights the effectiveness of integrating PWAS and autoantigenomics in exploring immune responses in COVID-19 and other diseases. It provides a deeper understanding of the autoimmunity landscape in human disorders and introduces a new bioresource for further investigation.Competing Interest StatementK Yamaguchi, T Okumura, C Ono, Y Kobayashi, A Miya, A Sato, and N Goshima were employed by ProteoBridge Corporation. T Fukasawa and A Yoshizaki belong to the Social Cooperation Program, Department of Clinical Cannabinoid Research, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, supported by Japan Cosmetic Association and Japan Federation of Medium and Small Enterprise Organizations. T Okamura belongs to the Social Cooperation Program, Department of Functional Genomics and Immunological Diseases, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, supported by Chugai Pharmaceutical Corporation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by The University of Tokyo Ethical Committee (Approval number 0695).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.